Chronic skin conditions, such as Psoriasis, are characterized by various symptoms including flaking, inflammation, and thick, white, silvery, or red patches of skin. OWC’s topical ointment was developed to alleviate these signs and symptoms.

OWC conducted extensive pre-clinical research that showed that the ointment inhibits keratocyte proliferation, which is a central aspect in Psoriasis. The study also showed lowering of various cytokines associated with inflammation in general (Il-8), and more specifically with Psoriasis (IL-33).

OWC has performed a 6-week safety study on 26 healthy subjects in one of Israel’s leading academic medical centers. The safety study demonstrated that the ointment remained topical with little to no penetration to the blood system (and thus induced no psychoactive side effects), and with nearly no local side effects. The pre-clinical study was performed at the Dead Sea Laboratory for Skin Biochemistry and Biotechnology in Ein Gedi, Israel. The subsequent safety clinical study was performed at a leading academic medical center in Israel.

OWC is currently in the process of obtaining all requisite approvals to initiate an efficacy study for its ointment formulation on Psoriasis patients.